We serve Chemical Name:3-Hydroxy-β-cyclocitral CAS:35692-94-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-Hydroxy-β-cyclocitral
CAS.NO:35692-94-5
Synonyms:MFCD24674228;1-Cyclohexene-1-carboxaldehyde, 4-hydroxy-2,6,6-trimethyl-;4-Hydroxy-2,6,6-trimethyl-1-cyclohexene-1-carbaldehyde;4-hydroxy-2,6,6-trimethylcyclohex-1-ene-1-carbaldehyde
Molecular Formula:C10H16O2
Molecular Weight:168
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:267.2±40.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.540
PSA:
Exact Mass:168.115036
LogP:1.68
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like MFCD24674228 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-hydroxy-2,6,6-trimethylcyclohex-1-ene-1-carbaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Hydroxy-2,6,6-trimethyl-1-cyclohexene-1-carbaldehyde Use and application,4-Hydroxy-2,6,6-trimethyl-1-cyclohexene-1-carbaldehyde technical grade,usp/ep/jp grade.
Related News: What’s the background? 3-Hydroxy-β-cyclocitral manufacturer Inceptua is a pharmaceutical company and service partner spanning throughout the product lifecycle �C from comparator sourcing for clinical trials, through early access programs to licensing and commercialization for products. 3-Hydroxy-β-cyclocitral supplier The insulin-only and bihormonal configurations may be helpful in diabetes. 3-Hydroxy-β-cyclocitral vendor The Company��s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). 3-Hydroxy-β-cyclocitral factory The Company��s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).
